According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
To create leading company developing medicines targeting metalloenzymes
To focus on providing safer burn treatments for women and armed forces
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Subscribe To Our Newsletter & Stay Updated
